Does Wellbutrin (bupropion) require a taper when discontinuing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Does Wellbutrin Require a Taper?

Yes, Wellbutrin (bupropion) should be tapered when discontinuing, particularly for patients on the 300 mg dose, to minimize withdrawal symptoms and prevent adverse outcomes. 1

FDA-Mandated Tapering Protocol

The FDA drug label explicitly states that when discontinuing bupropion extended-release 300 mg once daily, the dose must be decreased to 150 mg once daily prior to complete discontinuation. 1 This is the only antidepressant-specific tapering guidance provided in the evidence, making it the clearest directive available.

Rationale for Tapering

While bupropion has a different mechanism of action than SSRIs (it affects norepinephrine and dopamine rather than serotonin), antidepressant discontinuation syndrome can still occur:

  • All classes of antidepressants are associated with withdrawal syndromes, including those affecting different neurotransmitter systems. 2
  • Discontinuation symptoms commonly include insomnia, flu-like symptoms, mood disturbances, dizziness, anxiety, agitation, and irritability. 3, 4
  • Symptoms can last days to months and may be mistaken for relapse of depression or physical illness, leading to unnecessary testing and treatment. 3, 4

Recommended Tapering Approach

For patients on 300 mg daily:

  • Reduce to 150 mg once daily and maintain this dose for at least 1-2 weeks before complete discontinuation. 1
  • Monitor closely for withdrawal symptoms during this period. 3

For patients on 150 mg daily:

  • While the FDA label doesn't mandate tapering from 150 mg, general antidepressant principles suggest gradual discontinuation over weeks is prudent. 3, 4
  • Consider extending the interval between doses before complete cessation. 5

Tapering timeline:

  • Tapers should be carried out over weeks to months, not days. 3
  • Gradual tapering is necessary to minimize discontinuation symptoms. 4
  • The first dose reduction is critical—it must go well to predict tolerance of further reductions. 6

Managing Withdrawal Symptoms

If discontinuation symptoms emerge during tapering:

  • Restart the prior dose of bupropion that was well-tolerated. 3
  • Slow the taper further, using smaller decrements or longer intervals between reductions. 3, 4
  • Provide symptomatic management as needed for specific withdrawal symptoms. 3
  • Reassure patients that mild symptoms are usually transient and self-limiting. 4

Common Pitfalls to Avoid

  • Never abruptly discontinue bupropion, especially from the 300 mg dose, as this violates FDA guidance and increases withdrawal risk. 1
  • Don't mistake withdrawal symptoms for depression relapse—this can lead to unnecessary long-term medication continuation. 2, 3
  • Don't use overly rapid tapers (less than 2 weeks)—these show minimal benefit over abrupt discontinuation. 2
  • Don't dismiss patient concerns about withdrawal—validate their experience and adjust the taper accordingly. 3

Special Populations

Patients with hepatic impairment:

  • Maximum dose is 150 mg every other day for moderate-to-severe impairment, so tapering may require even more gradual dose reductions. 1

Patients with renal impairment:

  • Consider reducing dose and/or frequency, which may necessitate a more conservative tapering approach. 1

Monitoring During Discontinuation

  • Follow up within 1-2 weeks after each dose reduction to assess for withdrawal symptoms. 3
  • Screen for mood destabilization, anxiety, and sleep disturbances. 5, 3
  • Educate patients about expected withdrawal symptoms before initiating the taper to reduce anxiety and improve adherence. 3, 4

References

Research

Discontinuing antidepressants: Pearls and pitfalls.

Cleveland Clinic journal of medicine, 2022

Research

Clinical management of antidepressant discontinuation.

The Journal of clinical psychiatry, 1997

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antidepressant Tapering Is Not Routine But Could Be.

Journal of the American Board of Family Medicine : JABFM, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.